Clinical trials: Solid Organ Malignancies
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer
- Trial name
- NCT00002759
- Testing
- cyclosporine, irinotecan hydrochloride, phenobarbital
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumors, Acute Kidney Injury
Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers
This is a pilot, explorative, study to test the feasibility and safety of systemic infusion of donor ex-vivo expanded Mesenchymal Stem Cells to repair the kidney and improve function in patients with solid organ cancers who…
- Trial name
- CIS/MSC08 (NCT01275612)
- Testing
- Mesenchymal stromal cell infusion
- Where
- Italy
- Sponsor
- Mario Negri Institute for Pharmacological Research
Solid Tumor
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs).
- Trial name
- REDIRICT (NCT05301101)
- Testing
- Re-irradiation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Medical College of Wisconsin
Anal Cancer
Host Genome Methylation: a Screening Tool in Anal Cancer Detection
In January 2023, the first recommendations for anal cancer screening were issued by the French National Society of Coloproctology (SNFCP).
- Trial name
- AMethysT (NCT06792604)
- Testing
- Anal self-sampling (smear), HPV questionnaire
- Where
- 9 sites in France
- Volunteers
- 770 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer, Metastatic Cancer
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
The aim of this study is to assess the effectiveness of a battery of autoantibodies to predict the occurrence of immune-related adverse events (irAEs) in patients with cancer who will be treated with immune checkpoint inhibitors…
- Conditions
- Cancer, Metastatic Cancer, Solid Organ Cancer
- Trial name
- AUTENTIC (NCT03868046)
- Testing
- Treatment with immune checkpoint inhibitors., Blood tests.
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Hospital Universitario Araba
Malignancy, Transplant Complication
Epidemiology of Complications After Solid Organ Transplantation - EpCOT Study
Cancer remains a major cause of morbidity and mortality post solid organ transplantation. While mortality from the other leading causes of death post-transplantation (e.g.
- Conditions
- Malignancy, Transplant Complication, Cancer, Kidney Failure
- Trial name
- EpCOT (NCT02991105)
- Where
- 2 sites in United Kingdom
- Volunteers
- 85,410 people
- Sponsor
- University of Birmingham
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Covid19
Comorbidities and Risk Score in COVID-19 Patients
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included.
- Trial name
- Comorbidities (NCT04670094)
- Where
- 5 sites in Italy
- Volunteers
- 4,555 people
- Sponsor
- University of Milano Bicocca
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Chronic Disease, Immunocompromised
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting.
- Conditions
- Chronic Disease, Immunocompromised, HIV Infection, Chronic Kidney Disease
- Trial name
- AMBU-VAX (NCT07391046)
- Testing
- Hospital-Based Vaccination Pathway
- Volunteers
- 1,500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Solid Organ Cancers
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells.
- Trial name
- NCT02714374
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrew Lowy
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003252
- Testing
- amifostine trihydrate
- Where
- United States
- Sponsor
- Rush North Shore Medical Center
Invasive Fungal Infection, Hematological Malignancy
Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL
In patients with invasive fungal infection (IFI) rapid diagnosis is essential for early initiation of appropriate antifungal therapy and thereby survival. Conventional culture is still the Gold-Standard for diagnosis of IFI.
- Conditions
- Invasive Fungal Infection, Hematological Malignancy, Receipt of Solid Organ Transplant
- Trial name
- NCT01576653
- Testing
- Fungitell Assay in BAL
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Robert Krause, MD
Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
This is an open label, non-randomised, multicentre Phase I to determine the safety of tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their expansion/persistence with control EBV CTL in solid…
- Trial name
- ITREC (NCT03131934)
- Testing
- Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Lung Cancer
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
Amrubicin has shown single-agent activity in lung cancer. The combination of cyclophosphamide and anthracyclines has been studied and concluded that the combination was tolerable, could be given safely, and therapeutically…
- Trial name
- NCT00890955
- Testing
- Amrubicin, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lawrence Einhorn
Elderly Patients, Solid Organ Cancer
Epidural Anesthesia and Long-term Outcomes in Elderly Patients After Surgery
Surgical resection is one of the most important treatments for solid organ cancer. Whereas cancer recurrence and/or metastasis are the major reasons of treatment failure.
- Conditions
- Elderly Patients, Solid Organ Cancer, Surgical Resection, Epidural Anesthesia
- Trial name
- NCT03335826
- Testing
- Combined epidural-general anesthesia, General anesthesia
- Where
- 5 sites in China
- Volunteers
- 1,802 people
- Sponsor
- Peking University First Hospital
Malignant Lymphoma of Extranodal and/or Solid Organ Site, Solid Tumor
Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)
This is a single-arm, non-randomized feasibility and Phase I trial of 20(S) Camptothecin Propionate administered orally. CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity…
- Trial name
- NCT02575638
- Testing
- CZ48
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Cao Pharmaceuticals Inc.